Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Keith Katkin

Affiliations

  • Peo;ceo/urovant Sciences, Inc. at Urovant Sciences Ltd. (UROV), 2019-12-11
  • Director at Novus Therapeutics Inc. (NVUS), 2019-07-15
  • at Syndax Pharmaceuticals Inc (SNDX), 2019-06-12
  • Director at Rigel Pharmaceuticals Inc (RIGL), 2019-05-24
  • Director at Carbylan Therapeutics Inc. (CBYL), 2015-08-05
  • President And Ceo at Avanir Pharmaceuticals Inc. (AVNR), 2014-12-18
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
AVNR $2.61 10,000 Officer, Director 327,857 2012-03-06 Filing
AVNR $0.44 14,100 Officer, Director 593,442 2009-02-24 Filing
AVNR $0.43 900 Officer, Director 579,342 2009-02-24 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
UROV $12.78 120,000 Officer, Director 0 2019-12-09 Filing
AVNR $16.93 62,520 Officer, Director 914,249 2014-12-17 Filing
AVNR $16.95 195,160 Officer, Director 976,769 2014-12-15 Filing
AVNR $16.95 20,000 Officer, Director 976,769 2014-12-15 Filing
AVNR $11.76 27,567 Officer, Director 732,845 2014-10-24 Filing